{
    "clinical_study": {
        "@rank": "70627", 
        "arm_group": [
            {
                "arm_group_label": "Treatment group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive the investigational NTHi vaccine."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this group will receive placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this Phase II study is to assess the safety, reactogenicity and\n      immunogenicity of the investigational Non-typeable Haemophilus influenzae (NTHi) vaccine in\n      patients with moderate and severe persistent airflow obstruction."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to Patients With Persistent Airflow Obstruction", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Respiratory Disorders", 
        "condition_browse": {
            "mesh_term": [
                "Respiration Disorders", 
                "Respiratory Tract Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  A male or female between, and including, 40 and 80 years of age at the time of the\n             first vaccination.\n\n          -  Written informed consent obtained from the subject.\n\n          -  Confirmed diagnosis of COPD with forced expiratory volume in 1 second (FEV1) over\n             forced vital capacity (FVC) ratio (FEV1/FVC) < 0.7, AND FEV1 < 80% and  \u2265 30%\n             predicted.\n\n          -  Current or former smoker with a cigarette smoking history of \u2265 10 pack-years.\n\n          -  Stable COPD patient with documented history of at least 1 moderate or severe acute\n             exacerbation of COPD within the 12 months before Screening.\n\n          -  Regular sputum producer.\n\n          -  Capable to comply with the daily electronic Diary Card completion throughout the\n             study period, according to investigator's judgement at Visit 1.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/ product.\n\n          -  Use of any investigational or non-registered product other than the study vaccine\n             within 30 days preceding the first dose of study vaccine, or planned use during the\n             study period.\n\n          -  Planned administration/ administration of a vaccine not foreseen by the study\n             protocol in the period starting 30 days before the first dose and ending 30 days\n             after the last dose of vaccine, with the exception of any influenza or pneumococcal\n             vaccine which may be administered \u2265 15 days preceding or following any study vaccine\n             dose.\n\n          -  Previous vaccination with any vaccine containing NTHi antigens.\n\n          -  Administration of immunoglobulins or any blood products within the 3 months preceding\n             the first dose of study vaccine or planned administration during the study period.\n\n          -  Chronic administration of non-steroid immunosuppressants or other immune-modifying\n             drugs within 6 months prior to the first vaccine dose.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  History of immune-mediated disease other than COPD.\n\n          -  Administration of systemic corticosteroids within the 30 days before Screening.\n\n          -  Administration of systemic antibiotics within the 30 days before Screening.\n\n          -  Chronic use of antibiotics for prevention of acute exacerbations of COPD (AECOPD).\n\n          -  Receiving oxygen therapy.\n\n          -  Planned lung transplantation.\n\n          -  Planned/ underwent lung resection surgery.\n\n          -  Diagnosis of \u03b1-1 antitrypsin deficiency as the underlying cause of COPD.\n\n          -  Diagnosed with a respiratory disorder other than COPD, or chest X-ray/ CT scan\n             revealing evidence of clinically significant abnormalities not believed to be due to\n             the presence of COPD. Subjects with allergic rhinitis can be enrolled.\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccines and/ or the bronchodilator used for spirometry assessment during the\n             study.\n\n          -  Contraindication for spirometry testing.\n\n          -  Clinically significant abnormality in haematology or biochemistry parameter.\n\n          -  Acute cardiac insufficiency.\n\n          -  Malignancies within the previous 5 years or lymphoproliferative disorder.\n\n          -  Any known disease or condition likely to cause death during the study period.\n\n          -  Acute disease and/ or fever at the time of Screening.\n\n               -  Fever is defined as oral or axillary temperature \u2265 37.5\u00b0C. The preferred route\n                  for recording temperature in this study will be oral.\n\n               -  Subjects with acute disease and/ or fever at the time of Screening may be\n                  enrolled at a later date if enrolment is still open. Subjects with a minor\n                  illness without fever may be enrolled at the discretion of the investigator.\n\n          -  Pregnant or lactating female.\n\n          -  Current alcoholism and/or drug abuse.\n\n          -  Other condition which the investigator judges may put the safety of the subject at\n             risk through study participation or which may interfere with the study findings.\n\n          -  Planned move to a location that will complicate participation in the trial through\n             study end."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075541", 
            "org_study_id": "200157", 
            "secondary_id": "2013-003062-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment group", 
                "description": "Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.", 
                "intervention_name": "NTHi-10-AS01E", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.", 
                "intervention_name": "NaCl Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunogenicity", 
            "Observer-blind", 
            "Reactogenicity", 
            "Chronic Obstructive Pulmonary Disease", 
            "Safety"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to COPD Patients", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence of each solicited local adverse event (AE), in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (from day 0 - 6) following each vaccination."
            }, 
            {
                "measure": "Occurrence of each solicited general AE, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow-up period (from day 0 - 6) following each vaccination."
            }, 
            {
                "measure": "Occurrence of any unsolicited AE, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "During the 30-day follow-up period (from day 0 - 29) following each vaccination."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical laboratory abnormality, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 0."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical laboratory abnormality, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 7."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical laboratory abnormality, in all  subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 30."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical laboratory abnormality, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 60."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical laboratory  abnormality, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 67."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical  laboratory abnormality, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 90."
            }, 
            {
                "measure": "Occurrence of each haematological/ biochemical laboratory abnormality, in  all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 270."
            }, 
            {
                "measure": "Occurrence  of each haematological/ biochemical laboratory abnormality, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 450."
            }, 
            {
                "measure": "Occurrence of any potential immune-mediated disease (pIMD), in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "From first vaccination (Day 0) up to study conclusion (Day 450)."
            }, 
            {
                "measure": "Occurrence of any serious adverse event (SAE), in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "From first vaccination (Day 0) up to study conclusion (Day 450)."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075541"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Anti-vaccine component total IgG antibody concentrations as measured by ELISA, in all subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 0, Day 30, Day 60, Day 90, Day 270 and at Day 450."
            }, 
            {
                "measure": "NTHi-specific cell-mediated immune responses as measured by flow cytometry intracellular cytokine staining (ICS), in a sub-cohort of subjects.", 
                "safety_issue": "No", 
                "time_frame": "At Day 0, Day 90, Day 270 and at Day 450."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}